Floatz logo

Mechlorethamine

Cutaneous T-cell Lymphoma Stage I

Rochester Skin Lymphoma Medical Group, PLLCPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Cutaneous T-cell Lymphoma Stage I cohort.

Asset / SponsorPhaseRating
Triamcinalone
Rochester Skin Lymphoma Medical Group, PLLC
Phase 2B
Vorinostat
University of Washington
Phase 2CCC
Fenretinide
SciTech Development, Inc.
Phase 1CC

Same molecule, other indications

Mechlorethamine is also rated in:

mycosis fungoidesDormant
B
Indicative ·
63 / 100
View asset →
lymphomaDormant
B
Indicative ·
59 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →